Progestin+metformin: a fertility-sparing option for endometrial cancer

  • Mitsuhashi A & al.
  • J Gynecol Oncol
  • 1 Nov 2019

  • curated by Craig Hicks
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Medroxyprogesterone acetate (MPA) plus metformin is efficacious for treating patients for atypical endometrial hyperplasia (AEH) or endometrial cancer (EC), particularly those with BMI ≥25 kg/m2.

Why this matters

  • MPA plus metformin may offer an alternative to progestin alone as a fertility-sparing AEH and EC treatment, based on a high response rate, low recurrence rate, and good fertility outcomes

Study design

  • Researchers analyzed the health records of patients with EC or AEH treated with MPA 400 mg plus metformin 750-2250 mg per day (N=63; median age, 35 [range, 26-44] years; BMI ≥25 kg/m², 76%; insulin resistant, 68%).
  • Funding: None disclosed.

Key results

  • Overall complete response (CR) rate was 97% within 18 months.
  • Relapse occurred during follow-up in 13.1% of patients who achieved CR.
  • Overall relapse-free survival (RFS) at 5 years was 84.8%.
  • Patients with BMI ≥25 kg/m² had significantly better prognoses (OR, 0.19; P=.009).
  • Overall pregnancy and live birth rates were 61% and 45%, respectively.

Limitations

  • Retrospective, monocentric design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit